Clinical trial
Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In…
NCT00449046 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00449046 |
|---|---|
| Title | Clinical Assessment Of GW815SF Salmeterol/Fluticasone Propionate(HFA MDI) In Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study- |
| Official title | Clinical Assessment of GW815SF Salmeterol/Fluticasone Propionate (HFA MDI) in Pediatric Patients With Bronchial Asthma -A Long Term (24-week) Study- |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Bronchial Asthma |
| Intervention type | Drug |
| Interventions | GW815SF Salmeterol/Fluticasone propionate(HFA MDI) |
| Enrollment | 40 |
| Start date | Mar 1, 2007 |
| Primary completion | Nov 1, 2007 |
| Completion | Nov 1, 2007 |
| First posted | Mar 19, 2007 |
| Last update posted | May 6, 2015 |
| Countries | Japan |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: